Halozyme Therapeutics: ENHANZE Alone Is Well Worth A Huge Bet On This Underfollowed Biotech


The company appears to be on the right track, inking another ENHANZE deal, this time with Alexion. Is the path for growth as promising as it appears? PEG is poised for an important 2018; the prospects for the drug if approved are strong.



from Biotech News